Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

KALA BIO, Inc. (KALA)

$0.63 +3.92% NASDAQ: KALA · 15-min delayed
  • ARLINGTON, Massachusetts
  • Public · NASDAQ: KALA
  • 6 employees
$38.3MMarket cap
$0Revenue · FY2017
-$27.0MNet income
6Employees
KALANASDAQ
2017IPO

About KALA BIO, Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2017
$0
Net income
-$27.0M
Total assets
$9.5M
Market cap
$38.3M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$39.2M
Operating income
-$39.2M
Income tax
$0
Net income
-$27.0M
EPS (basic)
$-3.31
EPS (diluted)
$-3.31

Balance sheet

Total assets
$9.5M
Current assets
$9.5M
Total liabilities
$2.5M
Current liabilities
$2.5M
Shareholders’ equity
$7.0M

Cash flow

Operating cash flow
-$32.0M
Investing cash flow
-$15.0K
Financing cash flow
-$11.6M
Net cash flow
-$43.6M

Statements via Polygon.io (SEC filings)

NASDAQ: KALA
$0.63 +3.92%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.61 $981.50

52-week range

Market cap
$38.3M
EPS (diluted)
$-3.31
Shares outstanding
60.8M
Open
Day range
Prev close
Volume
IPO date
Jul 20, 2017

KALA BIO, Inc. (KALA) Stock Price

  • Reported a net loss of $27.0M in FY2017.
  • Trading 100% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review KALA BIO, Inc..

Write a review
Newsroom

News about KALA BIO, Inc.

News & sentiment via Polygon.io

FAQ

KALA BIO, Inc.: frequently asked questions

Is KALA BIO, Inc. an American company?

KALA BIO, Inc. is a US-based company headquartered in Arlington, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is KALA BIO, Inc. headquartered?

KALA BIO, Inc. is headquartered in Arlington, Massachusetts, United States.

Is KALA BIO, Inc. publicly traded?

Yes — KALA BIO, Inc. is a publicly traded company. Its stock trades under the ticker symbol KALA on the NASDAQ.

What does KALA BIO, Inc. do?

KALA BIO, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →